tbuckley/cabot-search huggingface dataset:
Abstract 235: Old Age Is Independently Associated with Short Duration of Cardiopulmonary Resuscitation
Authors: Tae Ho Song, Kyuseok Kim, Kyeong Won Kang, Won Chul Cha, Jae Hyuk Lee, You Hwan Jo, Tae Yun Kim, Yu Jin Kim, Jin Hee Lee, Joong Eui Rhee
Journal: Circulation (2011)

Introduction The optimal duration of cardiopulmonary resuscitation (CPR) is unknown. Also the factors associated with the duration of CPR are not well known. We investigated that the old age might be the independent factor for short duration of CPR. Methods A prospective database including out-of-hospital arrest patients who underwent CPR at one academic emergency department from 2008 through 2010 was analyzed retrospectively. Exclusion criteria were as follows: age under 18 years, traumatic causes of arrest, who gained ROSC. Patients were divided into two groups by the duration of CPR; the shorter group (CPR duration &lt; 30 minutes) and the prolonged group (CPR duration &gt; 30 minutes). Univariate and multivariate analyses were used to identify the factors associated with the short duration of CPR. Results A total of 168 patients were enrolled. The shorter group (106 patients) showed 63% of total patients whereas prolonged group (62 patients) showed 37%. Among the factors examined, old age (&gt;65years, adjusted odds ratio 2.072, 95% CI 1.044-4.111) and place where arrest took place were found to be independently associated with the short duration of CPR. Conclusion Old age might be one of the factors that is independently associated with the short duration of CPR.
Abstract 749: Highly potent and orally available SIK2 inhibitors block growth of human ovarian cancer cells in culture and xenografts
Authors: Albandri Alfredi, Shu Zhang, Weiqu Mao, Yan Wang, Hiroshi Takemori, Zhen Lu, Robert C. Bast, Hariprasad Vankayalapati
Journal: Cancer Research (2014)

Abstract Salt Inducible Kinase 2 (SIK2) is a Ser/Thr kinase required for centrosome splitting and bipolar mitotic spindle formation. SIK2 is overexpressed in 30% of ovarian cancers associated with a poor prognosis. Knockdown of SIK2 with siRNA has inhibited ovarian cancer cell growth and enhanced paclitaxel sensitivity in cell culture and in xenografts. Given the challenges of delivering siRNA to cancer cells in vivo, we have sought small molecule inhibitors of SIK2 to permit clinical trials, alone and in combination with paclitaxel. Fragment-based design strategies utilizing SIK2 ATP-binding site residues, scaffold-hopping, SIK2 binding assay and subsequent SAR have led to the discovery of potent, selective, orally bioavailable first-in-class SIK2 inhibitors. Here we describe the identification and the preclinical characterization of ARN-3236 and its novel analogue ARN-3252 belonging to the same chemical class, suitable for oral administration. ARN-3236 and ARN-3252 compounds are highly potent (IC50: 1 and 5 nM), ATP competitive SIK2 inhibitors, characterized by high selectivity when tested against a panel of more than 456 kinases. ARN-3236 and ARN-3252 potently blocked proliferation of human ovarian cancer cell lines with endogenous SIK2 activation including OVCAR-3, SKOv3, HEY and ES-2 with an IC50 between 0.5 to 3.0 nM. Inhibition of proliferation has been observed in 9 additional ovarian cancer cell lines. The ARN-3236 and ARN-3252 exhibit a promising in vitro ADME profile and favorable in vivo PK parameters in mice and rats, including oral bioavailability. When tested in vivo in three murine subcutaneous xenograft models employing OVCAR-3, SKOv3 and ES-2 cells, ARN-3236 displayed dose-dependent tumor growth inhibition following daily oral administration at 30, 60 and 100 mg/Kg, with tumor regression observed at these dose levels. The lead identification, optimization, SAR, PK, single agent efficacy, efficacy in combination with paclitaxel and dose-dependent target modulation and the maintenance of SIK2 phosphorylation inhibition data will be presented. Given these specific small molecule inhibitors, SIK2 may provide a valuable target for treatment of a subset of human ovarian cancers. Citation Format: Albandri Alfredi, Shu Zhang, Weiqu Mao, Yan Wang, Hiroshi Takemori, Zhen Lu, Robert C. Bast, Hariprasad Vankayalapati. Highly potent and orally available SIK2 inhibitors block growth of human ovarian cancer cells in culture and xenografts. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 749. doi:10.1158/1538-7445.AM2014-749
Abstract 1024: Glucose-6-Phosphate Dehydrogenase (G6PD) Functions as a Modulator of Contractile Function in Coronary Artery .
Authors: Rakhee S Gupte, Beverly C Floyd, Mark W Kozicky, Rikuo Ochi, Michael S Wolin, Sachin A Gupte
Journal: Circulation (2007)

Objective: Inhibition of G6PD has recently been demonstrated to relax precontracted coronary and pulmonary arteries. However, the mechanism underlying the modulation of vascular function following ...
Probiotic prophylaxis to prevent ventilator-associated pneumonia (VAP) in children on mechanical ventilation: an open-label randomized controlled trial—response to comments by Saptharishi et al.
Authors: Niranjan Biswal, Parameswaran Narayanan, Rangan Srinivasaraghavan, Balasubramaniam Banupriya
Journal: Intensive Care Medicine (2015)
Industry paid $6.5bn to US physicians and hospitals in 2014
Authors: Michael McCarthy
Journal: BMJ (2015)

The drainage pattern of the Canadian Shield is at least pre-Ordovician and its present destructional topography developed in pre-Paleozoic time. One or more of the features of localities in which details of the Ordovician-Precambrian surface have been described in the literature are generally diagnostic of a paleoplain now being exhumed. Data from the literature are summarized and an extensive review of the whole of the Canadian Shield is given. A bibliography is appended.
Abstract 16715: Is the Long Term Prognostic Benefit of Primary Angioplasty in the 'Real World' Statistically Lacking? An Analysis of 54,360 Patients with ST Elevation Myocardial Infarction
Authors: Sayan Sen, Darrel P Francis, Therese Tillin, Rodney A Foale, Iqbal Malik, Ghada W Mikhail, Nearchos Hadjiloizou, Resham Baruah, Andreas Kyriacou, Alun D Hughes, Jamil Mayet, Justin E Davies
Journal: Circulation (2010)
Comparison of Two Quality-of-Life Instruments for Cancer Patients: The Functional Assessment of Cancer Therapy-General and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30
Authors: Georg Kemmler, Bernhard Holzner, Martin Kopp, Martina Dünser, Raimund Margreiter, Richard Greil, Barbara Sperner-Unterweger
Journal: Journal of Clinical Oncology (1999)

To compare two quality-of-life (QOL) questionnaires for cancer patients, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy-General (Fact-G), on the basis of empirical data.Two hundred forty-four patients with a diagnosis of breast cancer or Hodgkin's disease completed both the EORTC QLQ-C30 and the FACT-G (German language version) during the same session. Questionnaire data were analyzed on a subscale basis using correlation analysis, canonical correlation, and multiple linear regression.Correlations between corresponding subscales of the FACT-G and the EORTC QLQ-C30 ranged from r =.14 for the social domain (very poor agreement) to r =.66 for the physical domain (good agreement), with r values for the other domains lying between these extremes. Canonical correlation analysis for the two sets of subscales revealed that overall agreement between the two instruments was only moderate (first canonical correlation coefficient r =.85, but overall redundancy less than 40%). Of the five FACT-G subscales, only one, physical well-being, was well represented by the EORTC QLQ-C30 subscales (multiple linear regression, R(2) =.67). Only three of eight EORTC QLQ-C30 subscales (physical functioning, global QOL, general symptoms) were represented fairly well by FACT-G subscales (R(2) =.43 to.60). The lowest R(2) values (<.15; ie, virtually no representation by the other instrument) were found for the FACT-G social well-being and relation with doctors and EORTC QLQ-C30 cognitive functioning subscales.For the sample investigated, the EORTC QLQ-C30 and the FACT-G were found to measure markedly different aspects of QOL, despite considerable overlap. Replicability provided, this implies that neither of the two QOL instruments can be replaced by the other and that a direct comparison of results obtained with the two instruments is not possible.
Asthma severity and body mass index relationship
Authors: Emin Maden, Turgut Teke, Sebnem Yosunkaya, Durdu Mehmet Yavsan, Mustafa Dinç, Rukiye Metineren
Journal: European Respiratory Journal (2011)

Obesity is considered as a risk factor for asthma; however the relationship between obesity and asthma control is being discussed. In this study we aimed to evaluate the relationship between obesity and disease severity in asthma patients.  Asthma patients diagnosed in our clinic (543 patients) were enrolled to study. BMI (kg/m 2 ) of the cases were analyzed. BMI was classified as low (BMI,  2 ), normal (18.5-24.9 kg/m 2 ), overweight (25-29.9 kg/m 2 ), obesity (BMI, > or = 30 kg/m 2 ), or morbid obesity (BMI, >34.9 kg/m 2 ). The patients were also grouped according to disease severity.  In this study, the mean age of asthmatic patients (417 female, 126 male) was 48.4±13.7. Of the patients 172 (31.7%) had mild intermittent asthma, 190 (35%) had mild persistent, 138 (25,4%) had moderate persistent and 43 (7.9%) had severe persistent asthma. Obese and morbid obese patients consisted of 52% of the asthma patients and only 1.8% of the patients were low weight and 17.7% of them were normal weight cases. Frequencies of obesity and morbid obesity in female asthmatics were higher than in male asthmatics (in females %33.8 and 23.7%, in males %19.8 and 14.3%). There was no difference between males and females with respect to asthma severity. Also no significant difference was found when we analyzed the relationship between asthma severity and obesity.  In conclusion, in our study we found that most of the asthma patients were obese or morbid obese; so obesity is a risk factor for asthma, however there is no significant relationship between obesity and asthma severity.
Abstract 388: Postconditioning Beyond The Heart: Postconditioning The Ischemic Kidney Attenuates Renal Reperfusion Injury
Authors: Shady M Eldaif, Jeremiah Deneve, Ning Ping Wang, Mario Mosunjac, Rong Jiang, Asger Granfeldt, Zhi-Qing Zhao, Robert A Guyton, Jakob Vinten-Johansen
Journal: Circulation (2007)

Objective : Postconditioning (Poc), defined as brief cycles of arterial occlusion and reflow applied at the onset of reperfusion (R), has proven to reduce multiple consequences of myocardial ischemia-reperfusion injury (I/R). The protective effects of Poc in the kidney I/R are not known. Therefore, we tested the hypothesis that Poc attenuates renal I/R injury via adenosine receptor (AR) activation and protein kinase C (PKC) signaling. Methods : The in vivo single kidney rat model was used. Rats underwent right nephrectomy and were randomized to 5 groups. A sham group (n=8) underwent the surgical and perfusion protocol without other interventions. In all remaining groups, the left renal artery is occluded for 45min and the left kidney was reperfused for 24 hours. Control group (n=8) received no intervention at R; Poc (n=8) underwent 4 cycles of 45 seconds R and 45 seconds of reocclusion at the onset of R. PC + ARi (n=6): the AR inhibitor 8-SPT (10mg/kg) was administered i.v. 5 minutes before Poc; Poc + PKCi: the PKC inhibitor, chelerytherine (5mg/kg), was administered i.v. 5 min before R. After 24 hours, renal function was assessed by plasma blood urea nitrogen (BUN) and creatinine (Cr), and the kidneys were harvested; apoptotic cells were quantified by TUNEL stain and morphological injury by H&amp;E staining. Results: Compared to sham, BUN and Cr were greater in control I/R group, which was significantly reduced in Poc (table ). Inhibition of AR or PKC stimulation reversed the reductions in BUN and Cr achieved by Poc. In addition, renal I/R increased the percentage of TUNEL positive cells in ten high powered fields vs Sham, which was reduced by Poc. Blockade of AR and PKC reversed the apoptosis reduction achieved by Poc. Conclusion: Postconditioning attenuates renal dysfunction and apoptosis induced by R injury and involves AR and PKC signaling. Poc suggests that R injury is triggered in early moments of reflow.
Follicular cutaneous T-cell lymphoma: beneficial effect of isotretinoin for persisting cysts and comedones
Authors: M Leverkus, C Rose, E B Bröcker, M Goebeler
Journal: British Journal of Dermatology (2005)

Journal Article Follicular cutaneous T‐cell lymphoma: beneficial effect of isotretinoin for persisting cysts and comedones Get access M. Leverkus, M. Leverkus Department of Dermatology and Venerology, Otto‐von‐Guericke‐University Magdeburg Leiptiger Str. 44 39120 Magdeburg, Germany Search for other works by this author on: Oxford Academic Google Scholar C. Rose, C. Rose Department of Dermatology, University of Würzburg, Josef‐Schneider‐Str. 2, 97080 Würzburg, Germany Search for other works by this author on: Oxford Academic Google Scholar E‐B. Bröcker, E‐B. Bröcker Department of Dermatology, University of Würzburg, Josef‐Schneider‐Str. 2, 97080 Würzburg, Germany Search for other works by this author on: Oxford Academic Google Scholar M. Goebeler M. Goebeler Department of Dermatology, University Hospital Mannheim University Heidelberg, Germany E‐mail: martin.leverhus@medizin.uni‐magdeburg.de Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 152, Issue 1, 1 January 2005, Pages 193–194, https://doi.org/10.1111/j.1365-2133.2005.06360.x Published: 01 January 2005
Impaired interferon signaling in chronic hepatitis C patients with advanced fibrosis via the transforming growth factor beta signaling pathway
Authors: Takayoshi Shirasaki, Masao Honda, Tetsuro Shimakami, Kazuhisa Murai, Takayuki Shiomoto, Hikari Okada, Riuta Takabatake, Akihiro Tokumaru, Yoshio Sakai, Taro Yamashita, Stanley M. Lemon, Seishi Murakami, Shuichi Kaneko
Journal: Hepatology (2014)

Malnutrition in the advanced fibrosis stage of chronic hepatitis C (CH-C) impairs interferon (IFN) signaling by inhibiting mammalian target of rapamycin complex 1 (mTORC1) signaling. However, the effect of profibrotic signaling on IFN signaling is not known. Here, the effect of transforming growth factor (TGF)-β signaling on IFN signaling and hepatitis C virus (HCV) replication was examined in Huh-7.5 cells by evaluating the expression of forkhead box O3A (Foxo3a), suppressor of cytokine signaling 3 (Socs3), c-Jun, activating transcription factor 2, ras homolog enriched in brain, and mTORC1. The findings were confirmed in liver tissue samples obtained from 91 patients who received pegylated-IFN and ribavirin combination therapy. TGF-β signaling was significantly up-regulated in the advanced fibrosis stage of CH-C. A significant positive correlation was observed between the expression of TGF-β2 and mothers against decapentaplegic homolog 2 (Smad2), Smad2 and Foxo3a, and Foxo3a and Socs3 in the liver of CH-C patients. In Huh-7.5 cells, TGF-β1 activated the Foxo3a promoter through an AP1 binding site; the transcription factor c-Jun was involved in this activation. Foxo3a activated the Socs3 promoter and increased HCV replication. TGF-β1 also inhibited mTORC1 and IFN signaling. Interestingly, c-Jun and TGF-β signaling was up-regulated in treatment-resistant IL28B minor genotype patients (TG/GG at rs8099917), especially in the early fibrosis stage. Branched chain amino acids or a TGF-β receptor inhibitor canceled these effects and showed an additive effect on the anti-HCV activity of direct-acting antiviral drugs (DAAs). Blocking TGF-β signaling could potentiate the antiviral efficacy of IFN- and/ or DAA-based treatment regimens and would be useful for the treatment of difficult-to-cure CH-C patients.
Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial.
Authors: A W Maksymiuk, J R Jett, J D Earle, J Q Su, F A Diegert, J A Mailliard, C G Kardinal, J E Krook, M H Veeder, M Wiesenfeld
Journal: Journal of Clinical Oncology (1994)

PURPOSE The combination of etoposide (E) and cisplatin (P) is an accepted standard therapy for small-cell lung cancer (SCLC); however, the optimal sequencing and administration schedule has not been defined. This study was designed to evaluate different sequencing and administration schedules of E and P in the treatment of SCLC. PATIENTS AND METHODS Five hundred fifty-two eligible patients with limited-(LD) and extensive-stage (ED) SCLC were randomized to receive one of the following regimens: arm A, P 30 mg/m2 by intravenous (IV) bolus followed by E 130 mg/m2 bolus; arm B, E 130 mg/m2 bolus followed by P 30 mg/m2 bolus; arm C, E 130 mg/m2 by 24-hour infusion and P 30 mg/m2 bolus at the end of each 24-hour infusion of E; arm D, E 130 mg/m2 by 24-hour infusion and P 45 mg/m2 by 24-hour infusion on day 2 and 3 only. Two 3-day induction cycles of IV EP were administered 4 weeks apart. Subsequent therapy was the same for all arms, consisting of four cycles of cyclophosphamide, doxorubicin, and vincristine (CAV) at 4-week intervals. Consolidative thoracic radiation therapy (TRT) and prophylactic cranial irradiation (PCI) were administered to responders. RESULTS The overall response rate (84%) was similar in all treatment arms. Treatment arm A was associated with the best complete response (CR) rate (52%), the most favorable median survival time (MST) of 15 months, and a 26% 2-year survival rate. Patients with LD on arm A had a MST of 20 months and a 42% 2-year survival rate. Multivariate analysis indicated that extent of disease, performance status, arm of therapy, and sex were significant independent factors influencing survival. Toxicity of the four regimens was similar, except for greater thrombocytopenia on arm D. CONCLUSION The bolus administration of EP with E following P for the first two cycles of chemotherapy was the most effective regimen, with especially encouraging survival for LD patients.
Hepatic venous pressure gradient in the preoperative assessment of patients with resectable hepatocellular carcinoma
Authors: Alessandro Cucchetti, Matteo Cescon, Rita Golfieri, Fabio Piscaglia, Matteo Renzulli, Flavia Neri, Alberta Cappelli, Federico Mazzotti, Cristina Mosconi, Antonio Colecchia, Giorgio Ercolani, Antonio Daniele Pinna
Journal: Journal of Hepatology (2015)
Relationship between DNA Ploidy and Functional Estrogen Receptors in Operable Prostate Cancer
Authors: O. (a) Nativ, T. (b) Umehara, D.S. (b) Colvard, T.M. (c) Therneau, G.M. (d) Farrow, T.C. (b) Spelsberg, M.M. (a) Lieber
Journal: European Urology (1997)
Predictors of six-minute walk distance at baseline and after three years in COPD patients
Authors: Renata Ferrari, Suzana Tanni, Laura Caram, Corina Corrêa, Camila Corrêa, Liana Coelho, Irma Godoy
Journal: European Respiratory Journal (2011)

Association between six-minute walk distance (6MWD) and COPD systemic markers overtime is unclear. The aim of this study was to verify the predictors of 6MWD at baseline and after three years in 53 COPD patients (66% male, age= 63±9 years, FEV1=56±21%). The following evaluations were undertaken at baseline and after three years: body mass index (BMI), six-minute walk distance (6MWD), Modified Medical Research Council dyspnea scale (MMRC) and Interleukin-6 (IL-6). Information on exacerbations was not available at baseline and was collected during the study period. At baseline, FEV1, MMRC, BMI, and IL-6 were included in a multiple linear regression analysis with the baseline 6MWD value as the dependent variable. After three years, we included the final values of the same variables with the final 6MWD value as the dependent outcome. In another model, we evaluated the influence of the number of exacerbations in the previous model. At baseline, FEV1 and IL-6 were selected as predictor of 6MWD (R2=0.44; p  Research supported by FAPESP (2010/08527-0). R. Ferrari is the recipient of a fellowship from FAPESP (2010/08557-6).
Early Predictive Factors of Survival in the Acute Respiratory Distress Syndrome
Authors: MEHRAN MONCHI, FLORENCE BELLENFANT, ALAIN CARIOU, LUC-MARIE JOLY, DOMINIQUE THEBERT, IVAN LAURENT, JEAN-FRANÇOIS DHAINAUT, FABRICE BRUNET
Journal: American Journal of Respiratory and Critical Care Medicine (1998)

To identify the potential impact of novel therapeutic approaches, we studied the early predictive factors of survival at the onset of acute respiratory distress syndrome (ARDS) in a 24-bed medical ICU of an academic tertiary care hospital. Over a 48-mo period, a total of 3,511 adult patients were admitted and 259 mechanically ventilated patients met ARDS criteria, as defined by American-European consensus conference, i.e., bilateral pulmonary infiltrates and PaO2 /Fi O2 lower than 200 without left atrial hypertension. These patients were randomly included in a developmental sample (177 patients) and a validation sample (82 patients). Demographic variables, hemodynamic and respiratory parameters, underlying diseases, as well as several severity scores (SAPS, SAPS-II, OSF) and Lung Injury Score (LIS) were collected. These variables were compared between survivors and nonsurvivors and entered into a stepwise logistic regression model to evaluate their independent prognostic roles. The overall mortality rate was 65%. SAPS-II, the severity of the underlying medical conditions, the oxygenation index (mean airway pressure × Fi O2 × 100/PaO2 ), the length of mechanical ventilation prior to ARDS, the mechanism of lung injury, cirrhosis, and occurrence of right ventricular dysfunction were independently associated with an elevated risk of death. Model calibration was very good in the developmental and validation samples (p = 0.84 and p = 0.72, respectively), as was model discrimination (area under the ROC curves of 0.95 and 0.92, respectively). Thus, the prognosis of ARDS seems to be related to the triggering risk factor, the severity of the respiratory illness, and the occurrence of a right ventricle dysfunction, after adjustment for a general severity score.